Novo Nordisk said Tuesday that fourth-quarter sales of Wegovy rose 17% on year. - Tom Little/Reuters Shares in Wegovy maker Novo Nordisk slid in early European trading Wednesday after guidance for the year ahead disappointed investors. In Copenhagen, the stock tumbled 19% at the opening bell after shares closed 15% lower in New York following Tuesday’s release of the company’s 2026 forecast. Most Read from The Wall Street Journal The Danish drugmaker said Tuesday that adjusted sales and operating profi ...